TREATMENT WITH GENETICALLY ENGINEERED BIOLOGICAL AGENTS: EFFICACY AND SAFETY OF CHANGEOVER

Aim: to assess efficacy and safety of «changeover» to the second genetically engineered biological agent (GEBA) in patients with juvenile idiopathic arthritis (JIA) with resistance or intolerability to the first GEBA. Patients and methods: the results of retrospective observational research of efficacy and safety of «changeover» to the second GEBA in 136 patients with various variants of JIA aged from 1 to 17 years old with primary resistance, partial effect or loss of efficacy to other biological agents are shown in this article. Among those 41 patient have systemic and 95 — JIA without extra-articular involvement. In 32 patients with JIA without extra-articular involvement the efficacy and safety of etanercept were assessed; in 63 — of adalimumab; in 22 patients with JIA and active extra-articular involvement — of tocilizumab, in 5 — of rituximab; in 14 patients with JIA without extra-articular involvement and active arthritis — of tumor necrosis factor (TNF) α inhibitors — adalimumab and etanercept. JIA was diagnosed according to the ILAR criteria. Results: in 6 and 12 months of treatment with the second GEBA inactive stage of disease / remission was detected in 65 and 84% of patients, respectively. In 13/22 patients with JIA and insufficient efficacy of rituximab remission was achieved in 24 weeks of follow-up after switching to the treatment with interleukin (IL) 6 receptors inhibitor, in 2/5 patients with resistance to tocilizumab — after switching to rituximab. In a year of treatment with etanercept as the second GEBA non-active stage / remission was induced in 100% of children with JIA without extra-articular involvement, in 85% — after switching to adalimumab, and in 100% of patients with JIA without extra-articular involvement — after administration of anti-TNF α-therapy. Conclusions: changeover to the second GEBA in patients with primary and secondary resistance or intolerability to the first GEBA allowed achieving of remission of systemic manifestations in patients with JIA and contributed to almost complete restoration of function in the joints in patients with JIA without extra-articular involvement and articular forms of JIA. Along with its high clinical efficacy the second GEBA was characterized by good tolerability and comparable safety profile.

1. Texbook of paediatric rheumatology. 6th Edn. J. Cassidy, R. Petty (eds.). Philadelphia: Saunders Elsevier. 2011.

2. Duffy C.M., Laxer R.M., Silverman E.D. Drug therapy for juvenile arthritis. Compr. Ther. 1989; 15 (10): 48–59.

3. Wahezi D.M., Ilowite N.T. Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives. Exp. Opin. Pharmacother. 2013; 14 (8): 975–989.

4. Horneff G. Update on biologicals for treatment of juvenile idiopathic arthritis. Exp. Opin. Biol. Ther. 2013;13 (3): 361–376.

5. Otten M.H., Anink J., Spronk S., van Suijlekom-Smit L.W. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Ann. Rheum. Dis. 2013; 72 (11): 1806–1812.

6. Emery P., Sebba A., Huizinga T.W. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann. Rheum. Dis. 2013; 72 (12): 1897–1904.

7. Beukelman T., Patkar N.M., Saag K.G., Tolleson-Rinehart S., Cron R.Q., DeWitt E.M. et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. (Hoboken). 2011; 63 (4): 465–482.

8. Tanjala P., Vahasalo P., Honkanen V. et al. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis. Ann. Rheum. Dis. 2009; 68: 552–557.

9. Otten M. N., Prince F. H., Armbrust W. et al. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register. Ann. Rheum. Dis. 2013; 72 (5): 721–727.

10. Giannini E.H., Ruperto N., Ravelli A. et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997; 40: 1202–1209.

11. Wallace C.A., Giannini E.H., Huang B., Itert L., Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res. (Hoboken). 2011; 63 (7): 929–936.

12. Karateev D.E. Modern approach to the problem of rapidly rheumatoid arthritis. Sovr. revmatol. = Current rheumatology. 2010; 2: 37–42.

13. Sigidin Ya.A., Lukina G.V. Biologicheskaya terapiya v revmatologii. 2-e izd., dop [Biological Therapy in Rheumatology. 2nd edit., enlarged]. Moscow, Prakticheskaya meditsina, 2009. 245 p.

14. Nam J., Villeneuve E., Emery P. The role of biomarkers in the management of patients with rheumatoid arthritis. Curr. Rheumatol. Rep. 2009; 11: 371–377.

15. . Klinicheskie rekomendatsii. Revmatologiya. Pod red. E.L. Nasonova [Clinical guidelines. Rheumatology. Ed. EL Nasonov]. Moscow, GEOTAR-Media, 2005. pp. 25–71, 120–140.

16. Fleischmann R. Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis. Exp. Opin. Drug. Saf. 2003; 2 (4): 347–365.

17. Baranov A.A., Alekseeva E.I., Bzarova T.M., Valieva S.I., Denisova R.V., Isaeva K.B., Karagulyan N.A., Litvitskii P.F., Mitenko E.V., Sleptsova T.V., Fetisova A.N., Chistyakova E.G., Taibulatov N.I., Morev S.Yu. Minutes of the management of patients with juvenile arthritis. Vopr. sovr. pediatrii = Current pediatrics. 2013; 12 (1): 37–56.

18. Hashkes P.J., Laxer R.M. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005; 294 (13): 1671–1684.

19. Nasonov E.L. Protivovospalitel'naya terapiya revmaticheskikh boleznei [Anti-inflammatory Therapy of Rheumatic Diseases]. Moscow, M-Siti, 1996. 345 p.

20. Tynjälä P., Vähäsalo P., Tarkiainen M., Kröger L., Aalto K., Malin M., Putto-Laurila A., Honkanen V., Lahdenne P. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann. Rheum. Dis. 2011; 70 (9): 1605–1612.

21. Visvanathan S., Wagner C., Marini J.C., Lovel D.J., Martini A., Petty R., Cuttica R., Woo P., Espada G., Gattorno M., Apaz M.T., Baildam E., Fasth A., Gerloni V., Lahdenne P., Quartier P., Saurenmann R., Travers S., Mendelsohn A., Xu S., Giannini E.H., Ruperto N., for the Paediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. Pediatr. Rheum. 2010; 8: 24.

22. Alexeeva E.I., Sleptsova T.V., Valieva S.I., Bzarova T.M., Denisova R.V., Isaeva K.B., Mitenko E.V., Chistyakova E.G., Fetisova A.N., Taibulatov N.I. Retrospective analysis of the efficacy and safety of methotrexate for subcutaneous administration in patients with juvenile idiopathic arthritis. Vopr. sovr. pediatrii = Current pediatrics. 2013; 12 (4): 38-46.

23. Deighton C., O’Mahony R., Tosh J. et al. Management of rheumatoid arthritis: summary of NICE guidance. BMJ. 2009; 338: 702.

24. Goekoop-Ruiterman Y.P.M., de Vries-Bouwstra J.K., Allaart C.F. et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005; 52: 3381–3390.

25. Soubrier M., Puechal X., Sibilia J. et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford). 2009; 48: 1429–1434.

26. Van Vollenhoven R.F. Treatment of rheumatoid arthritis: state of the art 2009. Nat. Rev. Rheumatol. 2009; 5: 531–541.

27. Hyrich K.L., Lunt M., Watson K.D. et al. British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007; 56: 13–20.

28. Pincus T., Yazici Y., Van Vollenhoven R. Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some setting? Need for longterm observations in standart care tocomplement clinical trials. J. Rheumatol. 2006; 33: 2372–2375.

29. Kovalenko V.M., Shuba N.M., Bortkevich O.P. et al. Zasto suvannya antagonіstіv faktora nekrozu pukhlin v lіkuvannі khvorikh na revmatichnі zakhvoryuvannya suglobіv (revmatoїdnii artrit, ankіlozivnii spondiloartrit, psorіatichna artropatіya). Metod. Rekomendatsії [Pose for Use of Tumor Necrosis Factor Antagonists in the Treatment of Rheumatic Joint Diseases (Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthropathy). Method. Recommendation]. Kiev, 2008. 40 p.

30. Ostergaard M., Unkerskov J., Linde L. et al. Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIOdatabase. Scand J. Rheumatol. 2007; 36: 151–154.

31. Blom M., Kievit W., Fransen J. et al. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J. Rheumatol. 2009; 36: 2171–2177.

32. Scrivo R., Conti F., Spinelli F.R. et al. Switching between TNF alpha antagonists in rheumatoid arthritis: personal experience and review of the literature. Reumatismo. 2009; 61: 107–117.

33. Hyrich K.L., Lunt M., Watson K.D. et al. British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007; 56: 13–20.

34. Smolen J.S., Kay J., Doyle M.K. et al.; GO-AFTER study investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosisin patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009; 374: 210–221.

35. Hehlgans T., Mannel D.N. The TNF–TNF receptors system. Biol. Chem. 2002; 383: 1581–1585.

36. Singh-Grewal D., Schneider R., Bayer N., Feldman B.M. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum. 2006; 54: 1595–1601.

37. Lomater C., Gerloni V., Gattinara M., Mazzotti J., Cimaz R., Fantini F. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J. Rheumatol. 2000; 27: 491–496.

38. Spiegel L.R., Schneider R., Lang B.A., Birdi N., Silverman E.D., Laxer R.M. et al. Early predictors of poor functional outcome in systemiconset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum. 2000; 43: 2402–2409.

39. Ringold S, Weiss F.P., Beukelman T., DeWitt E.M., Ilowite N.T., Kimura Y., Laxer R.M., Lovell D.J., Nigrovic P.A., Robinson A.B., Vehe R.K. 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis. Arthritis & Rheumatism. 2013; 65 (10): 2499–2512.

40. Alexeeva E.I., Valieva S.I., Bzarova T.M., Semikina E.L., Isaeva K.B., Lisitsyn A.O., Denisova R.V., Chistyakova E.G. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin. Rheumatol. 2011; 30 (9): 1163–1172.

41. Alexeeva E.I., Alekseeva A.M., Valieva S.I., Bzarova T.M., Denisova R.V. Vopr. sovr. pediatrii = Current pediatrics. 2008; 7 (2): 42–54.

42. Lovell D., Ruperto N., Reiff A., Jung L.K., Higgins G., Koné-Paut I., Jones Olcay Y., McIlraith M.J., Andhivarothai N., Kupper H., Giannini E.H., Peterson T., Martini A. Long-term efficacy and safety of adalimumab for up to 6 years in patients with juvenile idiopathic arthritis. Abstract presented at: 75th Annual scientific meeting of the American College of Rheumatology (ACR) and the 46th Annual meeting of the Association of Rheumatology Health Professionals (ARHP). Chicago, IL. USA. 2011. Abstract MIS (7190791).

43. Lovell D.J., Ruperto N., Reiff A., Jung L. K., Higgins G., Koné-Paut I. et al. OLE DE 038: Long-term efficacy and safety of ADA for up to 6 years in patients with JIA. ACR11. Arthritis Rheum. 2011; 63(10; Suppl.): abstract 265.

44. Breda L., Del Torto M., De Sanctis S., Chiarelli F. Biologics in children’s autoimmune disorders: Efficacy and safety. Eur. J. Pediatr. 2011; 170: 157–167.

45. Ruperto N., Lovell D.J., Reiff A., Gamir M., Higgins G., Koné-Paut I. et al. Long-term efficacy and safety of Adalimumab in 4–12 year old patients with juvenile idiopathic arthritis. Pediatr. Rheumatol. 2011; 9 (Suppl. 1): 26.

46. Lovell D.J., Ruperto N., Goodman S. Reiff A., Jung L Jarosova K. et al. Adalimumab with or without Methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med. 2008; 359: 810–820.

47. Kerensky T.A., Gottlieb A.B., Yaniv S., Au S.C. Etanercept: efficacy and safety for approved indications. Exp. Opin. Drug Saf. 2012; 11 (1): 121–139.

48. Beukelman T., Ringold S., Davis T.E., DeWitt E. M., Pelajo C. F., Weiss P. F., Kimura Y. Disease modifying anti-rheumatic drug use in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the CARRA Registry. J. Rheumatol. 2012; 39 (9): 1867–1874.

49. Trachana M., Pratsidou-Gertsi P., Pardalos G. Kozeis N., Badouraki M., Kanakoudi-Tsakalidou F. Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis. Scand. J. Rheumatol. 2011; 40: 101–107.

50. Russo R.A., Katsicas M.M. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J. Rheumatol. 2009; 36 (5): 1078–1082.

51. Frampton J.E. Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis. Paediatr. Drugs. 2013; 15 (6): 515–531.

52. De Benedetti F. Tocilizumab for systemic juvenile idiopathic arthritis. N. Engl. J. Med. 2013; 368 (13): 1256–1257.

53. De Benedetti F., Brunner H.I., Ruperto N., Kenwright A., Wright S., Calvo I.et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 2012; 367 (25): 2385–2395.

54. Alexeeva E.I., Bzarova T.M., Valieva S.I., Denisova R.V., Isaeva K.B., Chomakhidze A.M., Chistyakova E.G., Sleptsova T.V., Mitenko E.V., Taibulatov N.I. Efficacy and safety of human monoclonal antibodies to TNF α in children with juvenile idiopathic arthritis in primary and secondary ineffectiveness of other genetically engineered biological agents. Vopr. sovr. pediatrii = Current pediatrics. 2012; 11 (4): 82–88.

55. Bombardieri S., Ruiz A.A., Fardellone P., Geusens P., McKenna F., Unnebrink K. et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology. 2007; 46 (7): 1191–1199.

56. Curtis J.R., Xie F., Chen L. et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann. Rheum. Dis. 2011; 70: 1401–1406.